ArticleFrontiers in pharmacology2025
Icariin ameliorates minimal change disease by regulating the mitochondrial dysfunction pathway: an integrated strategy of network pharmacology, bioinformatics, and experimental validation.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ellagic Acid Prevents Obesity in High-Fat Diet-Fed Rats by Ameliorating Oxidative Stress via Modulation of the PPARG/STAT3/p-AKT1 Axis.Foods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Minimal change disease (MCD) involves mitochondrial dysfunction. Icariin (ICA) has therapeutic potential. However, the exact mechanism by which ICA regulates mitochondrial dysfunction remains to be elucidated. This study investigated ICA targets and mitochondrial dysfunction-related genes (MDRGs) involved in MCD pathogenesis. Methods: First, the differentially expressed genes (DEGs) between MCD and controls were identified using differential expression analysis. Differential MCD-ICA target genes were obtained by intersecting the DEGs and MDRGs with ICA target genes. The four Cytoscape algorithms were then used to screen the differential MCD-ICA target genes for candidates, which were then refined through expression validation, machine learning, and ROC analysis to pinpoint the key genes. Next, a nomogram model of MCD was constructed. Gene set enrichment analysis (GSEA), immune infiltration analysis, molecular regulatory network analysis, and molecular docking analysis were also performed using the key genes. Finally, reverse transcription quantitative polymerase chain reaction (RT-qPCR) was used to validate the expression of the key genes in rat samples. In parallel, mitochondrial morphology was examined using transmission electron microscopy, and the ATP content in renal tissue was measured using colorimetric detection. Results: Two key genes ( Conclusion:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.